Symptomatic Treatment of Subepithelial Infiltrates after Viral Conjunctivitis: Loteprednol or Dexamethasone?

Abstract

PURPOSE:

To compare the efficiency and ocular side-effect profile of topical loteprednol applied to one eye and topical dexamethasone applied to the other eye in the early period on the same patient who has subepithelial infiltrates (SEI).

METHODS:

The patients who developed bilateral SEI following epidemic keratoconjunctivitis (EKC) were applied topical loteprednol on one eye (group 2) and topical dexamethasone on the other (group 1).

RESULTS:

Decrease in the symptoms was faster in the dexamethasone group, but this difference between the groups was not statistically significant (p = 0.073). Both groups were found to have substantial recurrence. However, the difference between the groups was not statistically significant (p = 0.131).

CONCLUSIONS:

The study has found that in the treatment of SEI, which developed after EKC, statistically similar results can be obtained with loteprednol, which is known to have fewer adverse effects.

• Authors: Yusuf Koçluk, Emine Alyamaç Sukgen, Selim Cevher, Emrah Mat
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 25 Issue 5 Pg. 649-653 (Oct 2017) ISSN: 1744-5078 [Electronic] England
• PMID: 27015587 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Allergic Agents
• Glucocorticoids
• Ophthalmic Solutions
• Dexamethasone
• Loteprednol Etabonate

Topics

• Adenovirus Infections, Human (drug therapy)
• Administration, Ophthalmic
• Adolescent
• Adult
• Anti-Allergic Agents (adverse effects, therapeutic use)
• Child
• Conjunctivitis, Viral (drug therapy)
• Corneal Diseases (drug therapy, etiology)
• Corneal Stroma (drug effects, pathology)
• Dexamethasone (adverse effects, therapeutic use)
• Epithelium, Corneal (drug effects, pathology)
• Eye Infections, Viral (drug therapy)
• Female
• Glucocorticoids (adverse effects, therapeutic use)
• Humans
• Loteprednol Etabonate (adverse effects, therapeutic use)
• Male
• Middle Aged
• Ophthalmic Solutions
• Prospective Studies
• Treatment Outcome
• Visual Acuity (physiology)
• Young Adult